Our data demonstrated that the anti-CTLA-4 antibody, but not the anti-GITR antibody DTA-1, can induce significantly improved tumor-specific antitumor effects in combination with vvDD-IL-9 treatment. Here, TNFRSF18 is linked to neoplasm.